I propose to take Questions Nos. 61, 66 and 96 together.
I refer to the reply to Questions Nos. 139 of 2 February 1999 and 31, 55 and 102 of 3 March 1999 in which I indicated that I was not lobbied directly by the US National Security Adviser, Mr. Sander Berger, in relation to genetically modified crops. However, during the Taoiseach's visit to the United States in March 1998 the issue of Ireland's attitude to genetically modified products on the EU market was raised in the margins of unrelated meetings by members of the US administration, including Mr. Berger. This was conveyed to me by the Taoiseach's office in the context of Ireland's position on four marketing proposals which were considered at a meeting of EU member states on 18 March 1999.
I was not personally lobbied by representatives of any other Governments or by any commercial interests in connection with these four votes. However, a letter from the Canadian embassy to my colleague, the Minister for Agriculture and Food, in relation to one of the proposals, a genetically modified oilseed rape product, was passed on to me.
In the reply of 3 March 1999 I also placed on the record of the House my meeting in Dublin with the US Deputy Secretary of Agriculture, Mr. Richard Rominger, on 26 March 1998 during which the issue of Ireland's position on the marketing notifications was also raised. This meeting was a courtesy call on foot of a request from the United States in the course of a short visit to this country by Mr. Rominger and his wife. We discussed developments in genetic engineering, particularly in relation to environmental considerations. We did not discuss genetically modified foods specifically, as responsibility for legislation in this area rests with my colleague, the Minister for Health and Children.
With regard to the four marketing notifications on which member states were invited to vote at the meeting on 18 March 1999, three related to genetically modified maize products and one to a herbicide tolerant oilseed rape product. The four notifications had been referred by the European Commission to the relevant EU scientific committees and there was no reason to believe that they would cause any adverse effects on human health or the environment. All four notifications received qualified majority support and marketing consent was approved. Ireland supported only one of the maize products, sponsored by AgroEvo France, and abstained on the other three. While Ireland had not previously voted to approve the release of a genetically modified maize product, we previously voted in favour of a number of other genetically modified products, including soya beans, chicory and oilseed rape. At the March 1998 vote my overall preference was to abstain in individual votes pending the completion of the national consultation process. However, in the case in question, particularly in view of the advice from the EU scientific committees, I took the view that it would be inappropriate that this preference should affect the wider Community position. Ireland was represented at the meeting by an official of my Department who acted on my instructions.